Do analysts rate MOR or SLDB?

Solid Biosciences has a consensus price target of $17.00, indicating a potential upside of 93.40%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92

Is MOR or SLDB more profitable?

Solid Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Solid Biosciences' return on equity of -73.42% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Solid Biosciences N/A -73.42% -61.13%

Does the media refer more to MOR or SLDB?

In the previous week, Solid Biosciences had 1 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for MorphoSys. Solid Biosciences' average media sentiment score of 1.08 beat MorphoSys' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLDB or IDYA more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% IDEAYA Biosciences N/A -14.24% -13.09%

Does the media refer more to SLDB or IDYA?

In the previous week, Solid Biosciences had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for IDEAYA Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat IDEAYA Biosciences' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SLDB or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is SLDB or ELVN more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Enliven Therapeutics N/A -21.04% -20.41%

Does the media refer more to SLDB or ELVN?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for Enliven Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat Enliven Therapeutics' score of 0.12 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TARS or SLDB?

In the previous week, Tarsus Pharmaceuticals had 10 more articles in the media than Solid Biosciences. MarketBeat recorded 12 mentions for Tarsus Pharmaceuticals and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat Tarsus Pharmaceuticals' score of -0.09 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SLDB or ADPT?

In the previous week, Adaptive Biotechnologies had 10 more articles in the media than Solid Biosciences. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat Adaptive Biotechnologies' score of 0.58 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Solid Biosciences (SLDB) Competitors

$8.79 +0.49 (+5.90%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$8.85 +0.06 (+0.64%)

As of 07:05 AM Eastern

Compare

SLDB vs. MOR, IDYA, ELVN, TARS, and ADPT

Should you buy Solid Biosciences stock or one of its competitors? MarketBeat compares Solid Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solid Biosciences include MorphoSys (MOR), IDEAYA Biosciences (IDYA), Enliven Therapeutics (ELVN), Tarsus Pharmaceuticals (TARS), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.

How does Solid Biosciences compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Solid Biosciences has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, Solid Biosciences had 1 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for MorphoSys. Solid Biosciences' average media sentiment score of 1.08 beat MorphoSys' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Solid Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Solid Biosciences' return on equity of -73.42% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Solid Biosciences	N/A	-73.42%	-61.13%

Solid Biosciences has a consensus price target of $17.00, indicating a potential upside of 93.40%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Solid Biosciences beats MorphoSys on 14 of the 16 factors compared between the two stocks.

How does Solid Biosciences compare to IDEAYA Biosciences?

Solid Biosciences (NASDAQ:SLDB) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Solid Biosciences currently has a consensus target price of $17.00, suggesting a potential upside of 93.40%. IDEAYA Biosciences has a consensus target price of $50.69, suggesting a potential upside of 45.19%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Solid Biosciences is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

IDEAYA Biosciences' return on equity of -14.24% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

IDEAYA Biosciences has higher revenue and earnings than Solid Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
IDEAYA Biosciences	$218.71M	14.02	-$113.70M	-$1.60	N/A

Solid Biosciences has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

In the previous week, Solid Biosciences had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for IDEAYA Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat IDEAYA Biosciences' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IDEAYA Biosciences beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Enliven Therapeutics?

Solid Biosciences (NASDAQ:SLDB) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Enliven Therapeutics' return on equity of -21.04% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Solid Biosciences presently has a consensus price target of $17.00, indicating a potential upside of 93.40%. Enliven Therapeutics has a consensus price target of $63.40, indicating a potential upside of 30.45%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Solid Biosciences is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Enliven Therapeutics had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for Enliven Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat Enliven Therapeutics' score of 0.12 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Summary

Enliven Therapeutics beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Solid Biosciences has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Solid Biosciences	N/A	-73.42%	-61.13%

Tarsus Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$535.08M	5.32	-$66.42M	-$1.14	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, Tarsus Pharmaceuticals had 10 more articles in the media than Solid Biosciences. MarketBeat recorded 12 mentions for Tarsus Pharmaceuticals and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat Tarsus Pharmaceuticals' score of -0.09 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tarsus Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Tarsus Pharmaceuticals currently has a consensus price target of $90.67, indicating a potential upside of 37.02%. Solid Biosciences has a consensus price target of $17.00, indicating a potential upside of 93.40%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Tarsus Pharmaceuticals beats Solid Biosciences on 9 of the 16 factors compared between the two stocks.

How does Solid Biosciences compare to Adaptive Biotechnologies?

Solid Biosciences (NASDAQ:SLDB) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Adaptive Biotechnologies has higher revenue and earnings than Solid Biosciences. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Adaptive Biotechnologies	$276.98M	9.96	-$59.50M	-$0.33	N/A

Solid Biosciences currently has a consensus target price of $17.00, indicating a potential upside of 93.40%. Adaptive Biotechnologies has a consensus target price of $20.33, indicating a potential upside of 18.01%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Solid Biosciences has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

In the previous week, Adaptive Biotechnologies had 10 more articles in the media than Solid Biosciences. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat Adaptive Biotechnologies' score of 0.58 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.15, meaning that its share price is 115% more volatile than the broader market.

Summary

Solid Biosciences and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$817.13M	$3.45B	$6.45B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-4.51	19.75	24.66	23.99
Price / Sales	N/A	330.35	526.33	107.23
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	3.86	8.29	10.72	6.50
Net Income	-$174.32M	$23.85M	$3.56B	$336.88M
7 Day Performance	20.25%	2.87%	0.94%	-0.16%
1 Month Performance	32.78%	2.19%	0.36%	0.76%
1 Year Performance	80.86%	55.48%	29.67%	28.49%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.8483 of 5 stars	$8.79 +5.9%	$17.00 +93.4%	+94.9%	$817.13M	N/A	N/A	100	News Coverage Positive News
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
IDYA IDEAYA Biosciences	2.2454 of 5 stars	$31.23 -0.1%	$50.69 +62.3%	+63.0%	$2.75B	$218.71M	N/A	80
ELVN Enliven Therapeutics	2.6643 of 5 stars	$45.10 +0.5%	$63.40 +40.6%	+139.5%	$2.73B	N/A	N/A	50	Insider Trade Gap Down
TARS Tarsus Pharmaceuticals	2.8737 of 5 stars	$63.16 +1.0%	$90.67 +43.6%	+63.0%	$2.69B	$451.36M	N/A	50	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. MOR, IDYA, ELVN, TARS, and ADPT

How does Solid Biosciences compare to MorphoSys?

Summary

How does Solid Biosciences compare to IDEAYA Biosciences?

Summary

How does Solid Biosciences compare to Enliven Therapeutics?

Summary

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Summary

How does Solid Biosciences compare to Adaptive Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. MOR, IDYA, ELVN, TARS, and ADPT

How does Solid Biosciences compare to MorphoSys?

Which has stronger earnings and valuation, MOR or SLDB?

Does the media refer more to MOR or SLDB?

Which has more volatility and risk, MOR or SLDB?

Do insiders and institutionals have more ownership in MOR or SLDB?

Is MOR or SLDB more profitable?

Do analysts rate MOR or SLDB?

Summary

How does Solid Biosciences compare to IDEAYA Biosciences?

Do analysts rate SLDB or IDYA?

Is SLDB or IDYA more profitable?

Do insiders & institutionals hold more shares of SLDB or IDYA?

Which has better earnings and valuation, SLDB or IDYA?

Which has more volatility & risk, SLDB or IDYA?

Does the media refer more to SLDB or IDYA?

Summary

How does Solid Biosciences compare to Enliven Therapeutics?

Is SLDB or ELVN more profitable?

Which has higher valuation and earnings, SLDB or ELVN?

Do insiders and institutionals hold more shares of SLDB or ELVN?

Do analysts rate SLDB or ELVN?

Does the media refer more to SLDB or ELVN?

Which has more risk and volatility, SLDB or ELVN?

Summary

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Is TARS or SLDB more profitable?

Which has higher earnings and valuation, TARS or SLDB?

Does the media favor TARS or SLDB?

Do insiders & institutionals believe in TARS or SLDB?

Which has more volatility & risk, TARS or SLDB?

Do analysts rate TARS or SLDB?

Summary

How does Solid Biosciences compare to Adaptive Biotechnologies?

Do insiders and institutionals hold more shares of SLDB or ADPT?

Which has higher valuation and earnings, SLDB or ADPT?

Do analysts recommend SLDB or ADPT?

Is SLDB or ADPT more profitable?

Does the media prefer SLDB or ADPT?

Which has more volatility and risk, SLDB or ADPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools